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There is mounting evidence to support a role for the c-myc proto-
oncogene in tumour onset and progression. Myc directly modul-
ates the basal transcription apparatus, as well as specific genes
containing the consensus E-box element. Myc-responsive genes
include those whose protein products regulate the cell cycle and
cell death. Abnormal regulation of the c-myc gene by multiple
mechanisms can result in phenotypic transformation, aberrant cell
cycle control, and genomic instability. However, at present, only
its gene amplification and overexpression have been described in
breast cancer; neither gene rearrangement nor mutation have been
described. No clear relationships have yet been described between
c-myc amplification and overexpression of its mRNA nor protein
in breast cancer nor in other tumour types where c-myc is
commonly amplified (Varmus, 1984; Nass and Dickson, 1997;
Dang, 1999). 
In breast cancer, the chromosome 8 region where the gene is
localized has been identified as one of the three most commonly
amplified regions of the genome (Courjal et al, 1997); this region
also is commonly amplified in small cell lung carcinoma (Little et
al, 1985), leukaemia (Dalla-Farera et al, 1985), and colon carci-
noma (Alitalo et al, 1983). C-myc has been considered to be the
dominant oncogene in this region, driving the selection of this
amplification in cancer. This supposition is based on the common
expression of c-myc coupled with many demonstrations of its
oncogenic properties in multiple types of cancer models. For
example, in mouse transgenic models expression of the transgene
under either the MMTV or WAP promoter, or by retroviral
strategies, resulted in mammary tumours following multiple preg-
nancies (Leder et al, 1986; Edwards et al, 1988). 
These observations suggest that anomalous expression of c-myc
may bring about a cascade of effects: altered cell cycle progres-
sion, genomic instability, and in some instances, tumorigenesis. In
breast cancer, investigation of the relationship between the biolog-
ical function and the clinical implications of c-myc gene amplifica-
tion has produced inconsistent results. In an attempt to clarify the
clinical relevance of c-myc amplification in breast cancer we
performed a meta-analysis of the literature. To achieve this goal,
our meta-analysis set out to address three specific questions: 
1. What is the usual frequency of c-myc amplification in breast
tumours? 
2. Which prognostic factors are significantly associated with 
c-myc amplification, and how strong are the associations? 
3. To what degree is c-myc amplification in breast tumours asso-
ciated with disease relapse and/or survival? 
MATERIALS AND METHODS 
Source of articles and methods of citation search 
Articles evaluating c-myc amplification in human breast tumours
were identified through a literature search of the following data-
bases: Medline (National Library of Medicine, National Institutes
of Health, Bethesda, MD, USA), Current Contents (Institute for
Scientific Information, Philadelphia, PA, USA) and PubMed.
Knowledge Finder (Aries Systems Corp, North Andover, MA,
USA) was utilized as a search engine, with ‘amplification’, ‘on-
cogene’, ‘alteration’, ‘mutation’, ‘cancer’, and ‘breast’ used as
keywords for the search. Review articles and bibliographies from
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relevant papers were also used as means of identifying additional
studies. 
Inclusion and exclusion criteria 
For inclusion in this meta-analysis, studies had to describe
research determining the frequency of amplification of the c-myc
gene in human breast tumours, and provide the number of ampli-
fied and non-amplified tumours. Studies that did not differentiate
between gene amplification and other types of alteration
(rearrangement and deletions) were excluded from the analysis.
Multiple reports from the same study contributed only one esti-
mate to the calculation of overall c-myc amplification frequency
(Berns et al, 1992; Champeme et al, 1994; Scorilas et al, 1995).
However, subsequent reports containing new data on prognostic
factors or survival were also incorporated into pooled analyses of
the specific clinical end-points. Data from studies that used more
than one method to determine the overall frequency of amplifica-
tion were included separately in subgroup analyses of the
individual methods (Zhou et al, 1989; Watson et al, 1993).
Consideration of methodologic aspects included the sources of
tissue and amplification controls, specification of the positive
threshold for gene amplification, and a description of the char-
acteristics of the study population (Trock et al, 1997). 
For the association between c-myc amplification and a prog-
nostic factor to be analysed, at least three studies were required to
report data concerning that factor. Likewise, at least three studies
containing hazard estimates or raw data to generate survival 
estimates were required for the association between survival and 
c-myc amplification to be examined. This number is arbitrary 
and was thought to represent the minimum amount of data that
could provide an informative estimate of the magnitude of an
association. 
Methods of statistical analysis 
For each study the proportion of breast tumours with amplified 
c-myc was extracted and 95% confidence intervals were calculated
by standard methods (Fleiss, 1981). For a pooled measure of 
c-myc gene amplification frequency, the proportions from each
study were combined in a weighted average, using study sample
size as weights. Homogeneity of the proportions across studies
was determined using a chi-squared test for contingency tables.
(Fleiss, 1981). 
The association of c-myc amplification with individual prog-
nostic factors was expressed as a rate ratio (RR), i.e. the relative
probability of c-myc amplification in tumours with the adverse
prognostic factor compared to those without the adverse factor.
Study-specific RRs were pooled across all studies with a Mantel-
Haenszel approach (MH), using the procedure PROC FREQ in
SAS (Statistical Analysis Systems Institute Inc, Cary, NC). The
homogeneity of the RRs across the studies was determined using
the method of Breslow and Day (1987). 
The association between c-myc amplification and either overall
survival (OS) or disease-free survival (DFS) was derived as a
weighted average of study-specific estimates of the hazard ratio
(HR), using inverse variance weights (Kleinbaum et al, 1982).
This required the HR and its standard error (Tsuda et al, 1989;
Berns et al, 1992; Borg et al, 1992), or inclusion of sufficient raw
data in the published report for us to perform a multivariable
proportional hazards regression (Varley et al, 1987) (using PROC
PHREG in SAS). For studies that did not provide HR estimates or
the raw data (Yamashita et al, 1993; Lonn et al, 1995), we derived
estimates of the HRs by calculating the smallest HR that could be
detected with power = 0.80 at the P-values actually observed,
using standard power calculations for survival analysis (George
and Desu, 1974). The standard error of this derived HR estimate
was obtained by dividing the log (HR) estimate by the square-root
of the Wald chi-square statistic associated with the observed P-
value. As an ad hoc check on the validity of this approach we used
the same derivation in the three studies that did provide HRs. The
derived HRs from these three studies were in most instances
conservative, that is, they were generally smaller than those actu-
ally observed in the studies. 
RESULTS 
Results of citation search 
Forty reports were initially identified by our search. Eleven studies
that reported only data concerning over-expression of the c-myc
protein, or that did not distinguish between amplification and other
alterations of the c-myc gene were excluded. The analysis included
29 reports (representing 26 distinct studies) that met the inclusion
criteria. Twenty-six of the 29 reports were included in the estima-
tion of the overall proportion of c-myc-amplified tumors (Escot et
al, 1986; Cline et al, 1987; Varley et al, 1987; Bonilla et al, 1988;
Guerin et al, 1988; Adnane et al, 1989; Garcia et al, 1989; Tavassoli
et al, 1989; Tsuda et al, 1989; Zhou et al, 1989; Brouillet et al,
1990; Meyers et al, 1990; Munzel et al, 1991; Berns et al, 1992b;
Borg et al, 1992; Roux-Dosseto et al, 1992; Kreipe et al, 1993;
Nagayama and Watatani, 1993; Ottestad et al, 1993; Scorilas et al,
1993; Watson et al, 1996; Yamashita et al, 1993; Bieche et al, 1994;
Harada et al, 1994; Contegiacomo et al, 1995; Lonn et al, 1995).
Amplification data in Champeme et al (1994), Scorilas et al (1995)
and Berns et al (1992) were excluded from estimation of the overall
proportion, since they were originally reported in Bieche et al
(1994), Scorilas et al (1993) and Berns et al (1992b), respectively.
Of the 29 reports, 26 determined c-myc amplification by Southern
blot, three by slot blot (Tsuda et al, 1989; Zhou et al, 1989; Borg 
et al, 1992), and two by polymerase chain reaction (Watson et al,
1993; Lonn et al, 1995). Two studies utilized more than one method
(Zhou et al, 1989; Lonn et al, 1995). 
Seven prognostic factors were analysed for their association
with c-myc amplification: lymph node involvement (Escot et al,
1986; Cline et al, 1987; Varley et al, 1987; Adnane et al, 1989;
Tavassoli et al, 1989; Berns et al, 1992a; Borg et al, 1992; Kreipe
et al, 1993; Nagayama and Watatani, 1993; Scorilas et al, 1993;
Champeme et al, 1994; Harada et al, 1994; Lonn et al, 1995),
oestrogen receptor status (Escot et al, 1986; Varley et al, 1987;
Adnane et al, 1989; Garcia et al, 1989; Berns et al, 1992b; Borg et
al, 1992; Kreipe et al, 1993; Yamashita et al, 1993), progesterone
receptor status (Escot et al, 1986; Adnane et al, 1989; Garcia et al,
1989; Berns et al, 1992b; Borg et al, 1992; Kreipe et al, 1993;
Champeme et al, 1994), age (Escot et al, 1986; Guerin et al, 1988;
Adnane et al, 1989; Berns et al, 1992a; Borg et al, 1992; Kreipe et
al, 1993), menopausal status (Varley et al, 1987; Berns et al,
1992a; Borg et al, 1992; Yamashita et al, 1993), tumour size
(Guerin et al, 1988; Adnane et al, 1989; Nagayama and Watatani,
1993; Yamashita et al, 1993), and tumour grade (Escot et al, 1986;
Varley et al, 1987; Adnane et al, 1989; Garcia et al, 1989;
Tavassoli et al, 1989; Kreipe et al, 1993). Data on the HR for death1690 SL Deming et al
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or recurrence, as a function of c-myc amplification status, were
reported, or could be derived, in six studies (Varley et al, 1987;
Tsuda et al, 1989; Berns et al, 1992a; Borg et al, 1992; Yamashita
et al, 1993; Lonn et al, 1995). 
Methodologic assessment 
The studies were evaluated for the methods, analytic controls, and
thresholds utilized to determine the frequency of c-myc amplifica-
tion (Table 1). The primary sources of DNA controls were peri-
pheral blood lymphocytes (PBLs) or normal breast tissue. Studies
using PBLs exhibited a somewhat higher frequency of 
c-myc amplification (24.3%) and lower degree of variability 
(CV = 18.6%) than those using normal breast tissue (mean = 15.8%,
CV = 25.1%), although the difference was not significant, 
P = 0.180. Most studies used c-mos, β -globin, or β -actin as normal
gene controls for amplification. A two-fold increase was the most
common amplification threshold, used in 65% of the 23 studies
reporting a threshold. Most studies had adequate sample sizes,
with 90% studying more than 50 patients, and 62% more than 100.
A sample size of 50 gives reasonable precision for estimates of the
proportion of c-myc-amplified tumours, with 95% confidence
intervals in the range of ± 10–15 percentage points for most of 
the observed values of prevalence of amplification. The low per-
centage of small studies suggests that lack of statistical precision is
unlikely to be a major source of heterogeneity in this meta-
analysis. Only 41% of studies provided a description of the study
population that is adequate for deriving clinically useful infer-
ences; many did not indicate the prevalence of metastatic disease
or whether treatment was given prior to surgery. 
Proportion of c-myc-amplified tumours 
The proportion of c-myc-amplified breast tumours ranged from
1–50% (Figure 1). The estimate of the pooled average frequency of
c-myc amplification was (15.7% (95% CI = 12.5–18.8%), based on
the weighted average of 26 studies, comprising 3797 patients.
However, there was considerable heterogeneity across the studies
(χ 2 = 220.89, df = 25, P < 0.001), indicating that the pooled average
is an imprecise estimate of the amplification frequency to be
expected in any study. Some of the heterogeneity could be due to
differences in assay sensitivity and methods. Southern blotting was
the only method used in more than three studies, with an overall
frequency of 17.0% (95% CI = 13.5–20.5%). Slot blotting and PCR
methods demonstrated a lower level of amplification with frequen-
cies of 6.7% (95% CI = 0.1–14.3%) and (11.4% (95% CI = 0.4-
22.4%), respectively. The two studies that employed two methods
(Tsuda et al, 1989; Watson et al, 1993), Southern blotting and either
slot blotting or PCR, for determining gene amplification indicated
that both methods produced frequencies consistent with one
another, although the individual values were not provided. 
Clinical associations of c-myc amplification 
Association of c-myc amplification with known prognostic
factors 
There was no significant heterogeneity across studies in the asso-
ciation between c-myc and any of the prognostic factors, except for
age. Thus, it was valid to pool the estimates across studies for each
of the remaining six prognostic factors. Poor histopathological
grade, positive lymph node status, and negative progesterone
receptor status were each associated with a significantly greater
probability of c-myc amplification, while amplification was less
likely in tumours from post-menopausal women (Table 2).
Although we combined tumours with histopathological grades I
and II in the above analysis, there was a trend toward increasing
frequency of c-myc amplification with increasing grade, i.e. 12.5%
for grade I, 20.3% for grade II, and 31.4% for grade III tumours.
The association between lymph node status and c-myc amplifica-
tion did not vary according to the threshold used to define amplifi-
cation (data not shown). Because the association between c-myc
and each of the other prognostic factors was evaluated in relatively
few studies, the impact of the threshold for amplification could not
be assessed. 
Association with disease recurrence and overall survival 
The pooled estimates indicate that patients with c-myc-amplified
tumours are approximately twice as likely as those with a normal
level of c-myc to suffer disease recurrence or die (Tables 3A and
3B, respectively). For both disease-free (DFS) and overall survival
(OS), there was no significant heterogeneity of HRs across the six
studies. Exclusion of the two studies (Yamashita et al, 1993; Lonn et
al, 1995), where HRs were estimated from the P-values, still
resulted in approximately two-fold increases in risk. As with the
individual prognostic factors, there was relatively little variation in
Lonn, 1995
Watson, 1993
PCR methods
Borg, 1992
Zhou, 1989
Tsuda, 1989
slot blots
Contegiacomo, 1995
Harada, 1994
Bieche, 1994
Yamashita, 1993
Scorilas, 1993
Ottestad, 1993
Nagayama, 1993
Kreipe, 1993
Roux-Dossetto, 1992
Berns, 1992
Munzel, 1991
Meyers, 1990
Brouillet, 1990
Tavassoli, 1989
Garcia, 1989
Adnane, 1989
Guerin, 1988
Bonilla, 1998
Varley, 1987
Cline, 1987
Escot, 1986
Southern blot
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7
Proportion of breast tumours with c-myc amplification
Figure 1 Frequency of c-myc amplification in breast tumors by study and
method. Data represent the proportion of tumours with c-myc amplification
(boxes), and the 95% confidence interval around the proportion (bars). Box
sizes represent the relative sample size for each study. The dotted line
represents the weighted average over all studies for the proportion of c-myc-
amplified tumours. Studies are grouped according to the method used to
determine c-myc amplification. PCR = polymerase chain reaction 1692 SL Deming et al
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the threshold used to define c-myc amplification, so its influence
on associations with survival could not be assessed. 
Publication bias 
To evaluate publication bias (i.e. the phenomenon of studies with
null results being less likely to be published) we generated a funnel
plot of the reported frequency of c-myc amplification in each study
plotted against the corresponding sample size (as a surrogate for
the precision of the study). It is expected that the amount of scatter
around the true mean frequency should decrease as the study
sample sizes increase. The presence of publication bias would be
indicated by a void in the lower left-hand corner of the funnel plot,
suggesting a lack of small published studies presenting a low
frequency of amplification (Dickersin et al, 1992). Although this
method is subjective, Figure 2 suggests that a significant publica-
tion bias is unlikely in studies of c-myc amplification frequencies
of less than 10%, with four of these studies having a sample size ≤
100, one of which had a sample size of 54 (Figure 2). 
DISCUSSION 
Amplification of c-myc: prevalence in breast cancer 
Our results suggest that approximately one in six breast cancers
will display amplification of the c-myc gene. Because of the
heterogeneity in individual study-specific estimates of c-myc
amplification, this estimate may be less precise than suggested by
the calculated 95% confidence interval of 12.5-18.8%. Due to the
many potential technical and patient-related sources of variability
that could not be controlled in our analysis, such heterogeneity is
not surprising. Nevertheless, these data indicate that c-myc
amplification is likely to occur only slightly less frequently than
HER2/neu overexpression, a marker of apparent prognostic 
relevance in breast cancer. 
A number of factors may contribute to heterogeneity of results,
including tumour sampling variability, assay methodology, and
patient populations. The amount and type of tumour material
sampled may vary according to the surgical procedure and the size
of the tumour. With current diagnostic trends (fortunately) shifting
toward smaller tumours, research based on ‘convenience’ samples
may be over-represented by tumours large enough to provide suffi-
cient tissue for genetic analyses. In one study (Borg et al, 1992) the
analysed samples were noted to be only 10–15% of all breast
tumours diagnosed during that period. Sampling artifacts may also
be related to the amount and location of normal control tissue
taken at surgery, and perhaps, the area within the tumour that was
sampled. Previous studies have demonstrated that expression of 
c-myc varies within the tumour, and that c-myc amplification can
be seen in tissue at the leading edge of tumours (Watson et al,
1996). 
Until recently, amplification of the c-myc oncogene has been
evaluated by three principal methods: polymerase chain reaction,
slot blotting, and Southern blotting, with the latter being the most
widely utilized. These differing methodologies may have
contributed to the inconsistency of the reported values of c-myc
amplification, as they evaluate a mixed population of tumour and
non-tumour cells. The future more widespread use of technologies
that alleviate this problem, including fluorescence in situ
hybridization (FISH), should allow for a more accurate assessment
of gene amplification, deletions, and translocations by evaluating
gene alteration at the single-cell level. FISH would also provide
valuable information about the incidence of amplification in
various cell types, particularly in tumour samples that may
exhibit genetic heterogeneity. The usefulness of this technique in
assessing c-myc genetic alterations has been demonstrated in other
Table 2 The association of c-myc amplification with breast cancer prognostic factors 
Prognostic factor Studies (patients) Rate ratio (95% Cl) RR Test of homogeneity 
P-valuea χ 2 (df) P-valuea
Lymph node (+ vs –) 13 (1551) 1.24 (1.11–1.38) 0.001 13.15  (12) 0.379 
Oestrogen receptor (– vs +) 8 (1712) 1.13 (0.93–1.37) 0.227 4.03 (7) 0.683 
Progesterone receptor (– vs +) 7 (1636) 1.27 (1.08–1.49) 0.004 7.64 (6) 0.270 
Age (≥ 50 vs < 50 years) 6 (1055) bb 13.03 (5) 0.023 
Tumor grade (III vs I/II) 6 (551) 1.61 (1.19–2.17) 0.002 6.99 (5) 0.222 
Menopausal status (post vs peri/pre) 4 (697) 0.82 (0.69–0.97) 0.021 2.15 (3) 0.547 
Tumour size (≥ 2 cm vs < 2 cm) 4 (570) 1.10 (0.95–1.27) 0.219 2.10 (3) 0.557 
RR = rate ratio, i.e. the relative probability of amplified c-myc in tumours from patients in the first vs second category of the prognostic factor; CI = confidence
interval; df = degrees of freedom for test of homogeneity; aTwo-sided; bEstimates of the association between c-myc and age were not pooled across studies
because there was significant heterogeneity among the estimates 
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Figure 2 Funnel plot of studies of c-myc amplification in breast tumours.
Data represent the proportion of tumours exhibiting c-myc amplification in
each study plotted against the sample size of the study. The dotted line
represents the weighted average over all studies for the proportion of c-myc-
amplified tumours. The solid curved lines are an approximation of an
idealized ‘funnel shape’ expected in the absence of publication bias cancers, including prostatic and haematopoeitic malignancies
(Jenkins et al, 1997). It will also be of use for future studies to
utilize in situ hybridization and immunohistochemistry (IHC),
together with FISH, to provide a more comprehensive view of
amplification relative to overexpression, particularly since anti-
bodies suitable for IHC are now commercially available. 
Finally, the patient populations within each study may bias the
sample toward higher or lower prevalence of gene amplification,
or toward better or worse prognoses. Translating basic research on
the biology and function of tumour-associated genes to their eval-
uation in clinical populations requires attention to aspects of popu-
lation-based studies that can complicate interpretation of clinical
relevance. Details of tumour stage, metastatic prevalence, adjuvant
therapy, and average length of patient follow-up were frequently
omitted. The time period over which patients were accrued may
also be relevant, as it may identify differences in diagnostic or
treatment practices. 
Amplification of c-myc: role as an independent
prognostic factor 
Patients with c-myc amplified tumours had an approximate two-
fold increase in risk of relapse or death. For c-myc to be useful as
an independent prognostic factor, it should not be merely a surro-
gate for one or more established prognostic factors. Although 
c-myc amplification appears to be somewhat more common in
tumours with more aggressive phenotype (Table 2), it retained its
independent prognostic value in the four studies where survival
analyses were adjusted for lymph node metastasis, tumour size
and/or ER status. Thus, it is likely that c-myc has prognostic value
independent of these factors. Adjustment for tumour grade was
included in only one of the six survival studies, and this meta-
analysis has shown a significant correlation between high tumour
grade and c-myc amplification (RR = 1.61, Table 2). Thus, we
cannot rule out the possibility that the association between c-myc
and survival reflects, to some degree, a confounding influence
arising from the association between c-myc and grade. However,
for this association to be due entirely to confounding by grade
would require that the association between amplification and grade
be stronger (higher HR) than that observed between amplification
and survival. Thus, it is unlikely that grade explains all or most of
the association between c-myc and relapse or survival. 
Although survival was evaluated in only six studies, the above
data suggest that amplified c-myc may have significant value as an
independent prognostic factor. Table 3 shows that the magnitude of
the pooled HR estimates for DFS and OS are heavily influenced by
the large weight (small variance) of Berns et al (1992a). However,
the other five studies have individual HRs that are similar to or
larger than this, suggesting that the large weight of the latter
contributes toward a more conservative estimate. There is no
obvious source of bias that would produce this association with
survival as an artifact. Nevertheless, the retrospective nature of the
studies requires that this association be viewed as the starting point
for more rigorous assessment rather than an established prognostic
factor. Additional studies should optimally be embedded in random-
ized clinical trials to ensure uniform ascertainment and control of
confounding factors. Such studies could also allow distinction
between prognostic and predictive factors (Hayes et al, 1998). 
Little has been published about the effect of c-myc on treatment
response, particularly in breast cancer. New predictive factors are
needed, because conventional histopathologic factors do not accu-
rately predict the likelihood that an individual patient will respond
to cytotoxic chemotherapy. This is a possible area for future inves-
tigation, as some studies have implicated expression of c-myc in
resistance to cisplatin-based chemotherapy in multiple tumour
types (Walker et al, 1996), in MDR1 expression in rhabdomyo-
sarcoma cell lines (Prados et al, 1996), and in resistance to 5-
fluorouracil and cisplatin in squamous cell carcinomas of the head
and neck (Riva-Lavielle, 1994). A rigorous study, designed specif-
ically to address the relationship between c-myc amplification and
drug and hormone resistance in breast cancer, may provide valu-
able insight into more effective treatment strategies. 
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Table 3 Study-specific and pooled hazard ratio (HR) estimates of (A) disease-free survival and (B) overall survival in breast cancer patients with c-myc-
amplified tumours vs non-amplified tumours. 
Reference (n) Hazard ratio 95% CI Weighta Adjustment variables 
A
Yamashita et al, 1993 (77)b 3.02 0.72–12.59 1.88 LN, ER, size, menopausal status, erbB2, Rb, 
p53, int-2, NDP Kinase 
Varley et al, 1987 (35)b 4.11 0.48–35.43 0.83 Grade 
Tsuda et al, 1989 (176) 4.42 1.35–14.48 2.72  LN, size, erbB2, Tx 
Berns et al, 1992 (282) 1.80 1.30–2.60 28.41  LN, ER, size 
Borg et al, 1992 (311) 2.09 0.83–5.26 4.51  LN, ER, PR, size 
Lonn et al, 1995 (122)b 2.15 0.66–7.01 2.76 None 
Pooled estimate 2.05 1.51–2.78 Test of homogeneity, χ 2 = 3.47 (5 df), P = 0.63 
B
Yamashita et al, 1993 (77)b 4.79 1.45–15.79 2.70 LN, ER, size, menopausal status, erbB2, Rb, 
p53, int-2, NDP Kinase 
Varley et al, 1987 (35)b 1.99 0.36–10.90 1.32 None 
Tsuda et al, 1989 (176) 1.50 0.53–4.19 3.64  LN, size, erbB2, Tx 
Berns et al, 1992a (282) 1.40 1.00–2.20 18.81 LN, ER, size 
Borg et al, 1992 (311) 2.00 1.00–3.90 8.61  LN, ER, PR, size 
Lonn et al, 1995 (122)b 2.07 0.68–6.34 3.08 None 
Pooled estimate 1.74 1.27–2.39 Test of homogeneity, χ 2 = 4.0 (5 df), P = 0.55 
CI = confidence interval; LN = lymph node metastases; ER = oestrogen receptor status; PR = progesterone receptor status; Tx = treatment; 
aweight = 1/variance [ln (HR)]; bHR (hazard ratio) derived by authors of this meta-analysis as described in Methods 1694 SL Deming et al
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Amplification of c-myc in relation to other oncogenes 
It has been hypothesized that c-myc amplification is a marker for
genetic instability, and its permissive effect on downstream gene
amplification, or its interaction with co-factor mutations may
enhance the likelihood of disease progression to a more aggressive
phenotype. A study by Janocko et al (1995) found a preferential
sequence for gene amplification in breast cancer, with c-myc most
often occurring first, followed by c-erbB-2. Sierra et al (1999)
demonstrated in breast cancer patients that Bcl-2 overexpression
was strongly associated with lymph node metastasis, but only
when c-myc was co-expressed. Caspase 9 is a downstream co-
factor in myc-dependent tumourigenesis and progression. Deletion
of the gene encoding caspase 9 has been shown to block myc-
induced apoptosis and to further promote its oncogenic transfor-
mation (Soengas et al, 1999). These data are also consistent with
earlier reports implicating the 1p34–36 chromosomal region,
where the caspase 9 gene maps, as a locus of frequent deletion in
human tumours (Bieche et al, 1994; Mertens et al, 1997). These
studies provide further support for the examination of co-factor
mutations in the context of c-myc amplification as a means of
defining the prognostic value of this oncogene. 
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